Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

The cash injection comes as Biogen has been hit hard by the stalled rollout of its Alzheimer's disease drug Aduhelm (aducanumab), with Stat reporting earlier this month that the company is ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

New treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) enhance patient care with gene therapies and new mechanisms of action on the horizon, explained ...

Also Read: Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks Data ... Eylea (aflibercept) Injection 2 mg dosed every 4 weeks.

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

Please provide your email address to receive an email when new articles are posted on . One specialist argued that, in the future, gene therapy technologies will be the favored option for wet AMD.

It could also face a strong challenge if Eisai and Biogen get approval for a more convenient once-weekly, subcutaneous injection form of Leqembi, which is currently under FDA review. Approval for ...

Biogen's results beat estimates on strength ... expanding the company's product portfolio beyond its cosmetic injection Jeuveau. AbbVie forecasts 2025 profit above estimates on newer immunology ...